About Nardilysin
Nardilysin (NRDC) is a protein
from Homo sapiens identified by UniProt accession
O43847, 1151 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Nardilysin |
|---|
| UniProt accession | O43847 |
|---|
| Gene | NRDC |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1151 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.29
- unipolar depression · score 0.25
- platelet component distribution width · score 0.23
- platelet count · score 0.22
- major depressive disorder · score 0.20
- neoplasm · score 0.09
- esophageal squamous cell carcinoma · score 0.07
- rheumatoid arthritis · score 0.07
- hepatocellular carcinoma · score 0.07
- pancreatic ductal adenocarcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43847-F1 | alphafold | PREDICTED | 82.62 | — |
Amino-acid sequence (1151 residues)
MLRRVTVAAV CATRRKLCEA GRELAALWGI ETRGRCEDSA AARPFPILAM PGRNKAKSTC SCPDLQPNGQ DLGENSRVAR LGADESEEEG RRGSLSNAGD PEIVKSPSDP KQYRYIKLQN GLQALLISDL SNMEGKTGNT TDDEEEEEVE EEEEDDDEDS GAEIEDDDEE GFDDEDEFDD EHDDDLDTED NELEELEERA EARKKTTEKQ SAAALCVGVG SFADPDDLPG LAHFLEHMVF MGSLKYPDEN GFDAFLKKHG GSDNASTDCE RTVFQFDVQR KYFKEALDRW AQFFIHPLMI RDAIDREVEA VDSEYQLARP SDANRKEMLF GSLARPGHPM GKFFWGNAET LKHEPRKNNI DTHARLREFW MRYYSSHYMT LVVQSKETLD TLEKWVTEIF SQIPNNGLPR PNFGHLTDPF DTPAFNKLYR VVPIRKIHAL TITWALPPQQ QHYRVKPLHY ISWLVGHEGK GSILSFLRKK CWALALFGGN GETGFEQNST YSVFSISITL TDEGYEHFYE VAYTVFQYLK MLQKLGPEKR IFEEIRKIED NEFHYQEQTD PVEYVENMCE NMQLYPLQDI LTGDQLLFEY KPEVIGEALN QLVPQKANLV LLSGANEGKC DLKEKWFGTQ YSIEDIENSW AELWNSNFEL NPDLHLPAEN KYIATDFTLK AFDCPETEYP VKIVNTPQGC LWYKKDNKFK IPKAYIRFHL ISPLIQKSAA NVVLFDIFVN ILTHNLAEPA YEADVAQLEY KLVAGEHGLI IRVKGFNHKL PLLFQLIIDY LAEFNSTPAV FTMITEQLKK TYFNILIKPE TLAKDVRLLI LEYARWSMID KYQALMDGLS LESLLSFVKE FKSQLFVEGL VQGNVTSTES MDFLKYVVDK LNFKPLEQEM PVQFQVVELP SGHHLCKVKA LNKGDANSEV TVYYQSGTRS LREYTLMELL VMHMEEPCFD FLRTKQTLGY HVYPTCRNTS GILGFSVTVG TQATKYNSEV VDKKIEEFLS SFEEKIENLT EEAFNTQVTA LIKLKECEDT HLGEEVDRNW NEVVTQQYLF DRLAHEIEAL KSFSKSDLVN WFKAHRGPGS KMLSVHVVGY GKYELEEDGT PSSEDSNSSC EVMQLTYLPT SPLLADCIIP ITDIRAFTTT LNLLPYHKIV K
Explore Nardilysin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets